COVID-19

19 November, 2020

A novel optical biosensor for the early diagnosis of sepsis and severe Covid-19: the PROUD study

2024-03-29T13:55:21+03:00By hiss|Categories: Biomarkers, Publications|Tags: clinical trial, COVID-19, Sepsis|

Sarantia Doulou, Konstantinos Leventogiannis, Maria Tsilika, Matthew Rodencal, Konstantina Katrini, Nikolaos Antonakos, Miltiades Kyprianou, Emmanouil Karofylakis, Athanassios Karageorgos, Panagiotis Koufargyris, Gennaios Christopoulos, George Kassianidis, Kimon Stamatelopoulos, Robert Newberry, Evangelos J. Giamarellos-Bourboulis BMC Infectious Diseases 2020 Nov 19;20(1):860 DOI: 10.1186/s12879-020-05607-1Download pdf 🡇 Funding The study was funded in part by the Hellenic Institute

1 November, 2020

Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

2023-02-16T13:38:04+03:00By hiss|Categories: Publications|Tags: COVID-19, suPAR|

Tariq U Azam, Husam R Shadid, Pennelope Blakely, Patrick O'Hayer, Hanna Berlin, Michael Pan, Peiyao Zhao, Lili Zhao, Subramaniam Pennathur, Rodica Pop-Busui, Izzet Altintas, Jens Tingleff, Marius A Stauning, Ove Andersen, Maria-Evangelia Adami, Nicky Solomonidi, Maria Tsilika, Pinkus Tober-Lau, Eleni Arnaoutoglou, Verena Keitel, Frank Tacke, Athanasios Chalkias, Sven H Loosen, Evangelos J. Giamarellos-Bourboulis, Jesper

1 November, 2020

Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus

2024-03-29T13:45:05+03:00By hiss|Categories: Pathogenesis, Publications|Tags: COVID-19|

Georgios Renieris, Konstantina Katrini, Christina Damoulari, Karolina Akinosoglou, Christos Psarrakis, Magdalini Kyriakopoulou, George Dimopoulos, Malvina Lada, Panagiotis Koufargyris, Evangelos J. Giamarellos-Bourboulis Shock 2020 Nov;54(5):633-637 DOI: 10.1097/SHK.0000000000001562Download pdf 🡇 Funding GR is funded from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement grant European Sepsis Academy (agreement

8 July, 2020

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

2024-03-29T13:31:59+03:00By hiss|Categories: Pathogenesis, Publications|Tags: Anakinra, COVID-19|

George Dimopoulos, Quirijn de Mast, Nikolaos Markou, Maria Theodorakopoulou, Apostolos Komnos, Maria Mouktaroudi, Mihai G Netea, Themistoklis Spyridopoulos, Rebecca J Verheggen, Jacobien Hoogerwerf, Alexandra Lachana, Frank L van de Veerdonk, Evangelos J. Giamarellos-Bourboulis Cell Host & Microbe 2020 Jul 8;28(1):117-123.e1 DOI 10.1016/j.chom.2020.05.007Download pdf 🡇 Funding The study was funded in part by the

1 June, 2020

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

2024-04-01T07:03:28+03:00By hiss|Categories: Pathogenesis, Publications|Tags: COVID-19|

Evangelos J. Giamarellos-Bourboulis, Mihai G Netea, Nikoletta Rovina, Karolina Akinosoglou, Anastasia Antoniadou, Nikolaos Antonakos, Georgia Damoraki, Theologia Gkavogianni, Maria-Evangelia Adami, Paraskevi Katsaounou, Maria Ntaganou, Magdalini Kyriakopoulou, George Dimopoulos, Ioannis Koutsodimitropoulos, Dimitrios Velissaris, Panagiotis Koufargyris, Athanassios Karageorgos, Konstantina Katrini, Vasileios Lekakis, Mihaela Lupse, Antigone Kotsaki, George Renieris, Danai Theodoulou, Vassiliki Panou, Evangelia Koukaki, Nikolaos Koulouris,

1 June, 2020

ACTIVATE-II

2023-01-09T12:12:57+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: BCG, COVID-19|

Completed study Official Study Title A randomized clinical trial for enhanced trained immune responses through Bacillus Calmette-Guérin vaccination to prevent infections by COVID-19 Brief Description ACTIVATE-II is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination exists in

28 May, 2020

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection

2023-02-16T14:28:59+03:00By hiss|Categories: Publications|Tags: COVID-19|

Mihai G Netea, Evangelos J. Giamarellos-Bourboulis, Jorge Domínguez-Andrés, Nigel Curtis, Reinout van Crevel, Frank L van de Veerdonk, Marc Bonten Cell 2020 May 28;181(5):969-977 DOI 10.1016/j.cell.2020.04.042 View article 🡇 Funding M.G.N. was supported by an ERC advanced grant (833247) and a Spinoza grant of the Netherlands Association for Scientific Research.

1 May, 2020

ACHIEVE

2023-01-09T12:17:31+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: clarithromycin, COVID-19|

Completed study Official Study Title Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial Brief Description ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory

30 April, 2020

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

2023-02-16T14:29:21+03:00By hiss|Categories: Biomarkers, Publications|Tags: COVID-19, suPAR|

Nikoletta Rovina, Karolina Akinosoglou, Jesper Eugen-Olsen, Salim Hayek, Jochen Reiser, Evangelos J. Giamarellos-Bourboulis Critical Care 2020 Apr 30;24(1):187 DOI: 10.1186/s13054-020-02897-4View article 🡇 Funding The study was funded by unrestricted educational grants provided by the Hellenic Institute for the Study of Sepsis. Funds were also provided by Rush University Medical Center. Keywords: COVID-19;

1 April, 2020

SAVE

2024-10-18T12:29:07+03:00By hiss|Categories: Completed, Interventional, Sepsis and severe infections, Studies|Tags: Anakinra, COVID-19|

Completed study Official Study Title suPAR-guided Anakinra treatment for Validation of the risk and Early management of severe respiratory failure by COVID-19: the SAVE open-label, non-randomized single-arm trial Brief Description SAVE is an open non-randomized clinical trial aiming to study the early treatment of patients with COVID-19 pneumonia with anakinra guided by the biomarker